{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:04:58Z","timestamp":1762459498279,"version":"3.37.3"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T00:00:00Z","timestamp":1490140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with indolent non\u2010Hodgkin lymphoma (NHL) have multiple treatment options yet there is no consensus as to the best initial therapy. Lenalidomide, an immunomodulatory agent, has single agent activity in relapsed lymphoma. This trial was conducted to assess feasibility, efficacy, and safety of adding lenalidomide to rituximab, cyclophosphamide, and dexamethasone (LR\u2010CD) in untreated indolent NHL patients requiring therapy. This was a single institution phase II trial. Treatment consisted of IV rituximab 375\u00a0mg\/m<jats:sup>2<\/jats:sup> day 1; oral lenalidomide 20\u00a0mg days 1\u201321; cyclophosphamide 250\u00a0mg\/m<jats:sup>2<\/jats:sup> days 1, 8, and 15; and dexamethasone 40\u00a0mg days 1, 8, 15, and 22 of a 28\u2010day cycle. Treatment continued 2 cycles beyond best response for a maximum of 12 cycles without rituximab maintenance. Thirty\u2010three patients were treated. Median age was 68 (43\u201383 years). 39% had stage IV disease. Histologic subtypes included 8 follicular lymphoma (FL), 7 marginal zone lymphoma (MZL) (1 splenic, 2 extranodal, and 4 nodal), 15 Waldenstr\u00f6m's macroglobulinemia (WM), 1 lymphoplasmacytic lymphoma, 1 small lymphocytic lymphoma, and 1 low\u2010grade B\u2010cell lymphoma with plasmacytic differentiation (unable to be classified better as MZL or LPL). Hematologic toxicity was the most common adverse event. Median time of follow\u2010up was 23.4 months (range 1.8\u201350.9). The overall response rate was 87.9%, with 30.3% complete response. The median duration of response was 38.7 months. The median progression free survival was 39.7 months, while median overall survival (OS) has not yet been reached. Lenalidomide can be safely added to a simple regimen of rituximab, oral cyclophosphamide, and dexamethasone and is an effective combination as initial therapy for low\u2010grade B\u2010cell NHL.<\/jats:p>","DOI":"10.1002\/ajh.24693","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T12:12:50Z","timestamp":1487851970000},"page":"467-472","source":"Crossref","is-referenced-by-count":15,"title":["A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR\u2010CD) for untreated low\u2010grade non\u2010Hodgkin lymphoma requiring therapy"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-3163","authenticated-orcid":false,"given":"Allison","family":"Rosenthal","sequence":"first","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Ansell","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Gano","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Conley","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Camoriano","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Mikhael","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Keith Stewart","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Inwards","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Noel","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Porrata","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Russell","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Colgan","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodger","family":"Tiedemann","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Reeder","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6546"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V122.21.509.509","article-title":"Updated 6 year follow\u2010up of the PRIMA Study confirms the benefit of 2\u2010year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy","volume":"122","author":"Seymour JF","year":"2013","journal-title":"Blood."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5367"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv102"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.95"},{"key":"e_1_2_7_16_1","first-page":"8030","article-title":"A phase I\/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed\/refractory mantle cell lymphoma (MCL) with early evidence of efficacy","volume":"25","author":"Wang M","year":"2007","journal-title":"ASCO Meeting Abstracts."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.9258"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22053"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12755"},{"key":"e_1_2_7_22_1","first-page":"8521","article-title":"CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma","volume":"32","author":"Martin P","year":"2014","journal-title":"ASCO Meeting Abstracts."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.9926"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0862"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0154"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-258624"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24693","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24693","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.24693","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:09:33Z","timestamp":1694718573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/ajh.24693"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24693","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"type":"print","value":"0361-8609"},{"type":"electronic","value":"1096-8652"}],"subject":[],"published":{"date-parts":[[2017,3,22]]}}}